Your session is about to expire
← Back to Search
Tricyclic Antidepressant + Anticonvulsant
Migraine Medications for Tinnitus
Phase 4
Recruiting
Led By Hamid R Djalilian, MD
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
Drug Has Already Been Approved
Pivotal Trial
Summary
This trial tests two different medication combinations to help people with tinnitus. One group gets nortriptyline and topiramate, another gets verapamil and paroxetine. The goal is to see if these medications can reduce the stress and anxiety caused by tinnitus. Paroxetine has been studied previously for its potential to relieve tinnitus symptoms.
Who is the study for?
This trial is for adults aged 25-85 with moderate to severe tinnitus. Participants must be able to read and write English, attend study visits, and comply with medication regimens. Pregnant individuals, those with adverse reactions to the medications being tested or certain medical conditions are excluded.
What is being tested?
The trial tests if migraine medications can help treat tinnitus. It compares the effectiveness of Nortriptyline plus Topiramate versus Verapamil plus Paroxetine against a placebo in reducing the impact of tinnitus on daily life.
What are the potential side effects?
Potential side effects may include dry mouth, constipation, weight changes from Nortriptyline; numbness or tingling from Topiramate; low blood pressure or dizziness from Verapamil; and nausea or sleep disturbances from Paroxetine.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Tinnitus Functional Index (TFI)
Secondary study objectives
Patient Health Questionnaire (PHQ)
Perceived Stress Scale (PSS)
Sleep Quality Index (SQI)
+1 moreAwards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Verapamil + paroxetineExperimental Treatment1 Intervention
Verapamil (30 mg) plus paroxetine (4 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 30mg weekly (to a maximum of 240mg) for verapamil, and by 4mg weekly (maximum 32mg) for paroxetine.
Group II: Nortriptyline + topiramateExperimental Treatment1 Intervention
Nortriptyline (7.5 mg) plus topiramate (10 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 7.5mg weekly (to a maximum of 60mg) for nortriptyline, and by 10mg weekly (maximum 80mg) for topiramate.
Group III: PlaceboPlacebo Group1 Intervention
Placebo pill.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for tinnitus, particularly antidepressants and anxiolytics, work by addressing the psychological distress that often accompanies the condition. Antidepressants, such as SSRIs and SNRIs, function by increasing the levels of neurotransmitters like serotonin and norepinephrine in the brain, which can improve mood and reduce anxiety.
Anxiolytics, such as benzodiazepines, enhance the effect of the neurotransmitter GABA, leading to a calming effect on the nervous system. These mechanisms are crucial for tinnitus patients as they help alleviate the emotional and psychological burden of tinnitus, thereby improving their overall quality of life.
Find a Location
Who is running the clinical trial?
University of California, IrvineLead Sponsor
562 Previous Clinical Trials
1,932,362 Total Patients Enrolled
3 Trials studying Tinnitus
223 Patients Enrolled for Tinnitus
Hamid R Djalilian, MDPrincipal InvestigatorUniveristy of California, Irvine
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You had a bad reaction to the medication before.You have moderate to severe ringing in your ears.You are between 25 and 85 years old.You have ongoing, bothersome ringing or buzzing in your ears.You are between 25 and 85 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Verapamil + paroxetine
- Group 2: Nortriptyline + topiramate
- Group 3: Placebo
Awards:
This trial has 4 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Tinnitus Patient Testimony for trial: Trial Name: NCT04404439 — Phase 4
Share this study with friends
Copy Link
Messenger